New Lacutamab Data From Tellomak Trial to be Showcased in Oral Presentation at Upcoming 16th International Conference on Mali...
09 Juin 2021 - 12:00PM
Innate Pharma SA (Euronext Paris: IPH – ISIN: FR0010331421; Nasdaq:
IPHA) (“
Innate” or the “
Company”)
today announced that preliminary mycosis fungoides data from the
Phase 2 TELLOMAK trial evaluating lacutamab, an anti-KIR3DL2
cytotoxicity-inducing antibody in development for T-cell lymphomas,
will be presented during an oral presentation at the virtual 16th
International Conference on Malignant Lymphoma (16-ICML) taking
place from June 18-22, 2021.
Oral presentation details: |
Title: Lacutamab in patients with advanced mycosis
fungoides according to KIR3DL2 expression: early results from the
TELLOMAK phase 2 trial |
Date and time: June 22, 2021 at 1 p.m. CEST |
Abstract number: 054 |
TELLOMAK trial investigator, Martine Bagot,
M.D., Ph.D., Professor of Dermatology, Head of the Dermatology
Department at the Saint-Louis Hospital, University of Paris, will
deliver the oral presentation.
Pr. Bagot will also present the data during an
Innate Pharma online webcast for the financial community on June
23, 2021. Details about this webcast will be provided on the
Company website by June 16, 2021.
About Lacutamab:
Lacutamab (IPH4102) is a first-in-class
anti-KIR3DL2 humanized cytotoxicity-inducing antibody, which is
currently in clinical trials for treatment of cutaneous T-cell
lymphoma (CTCL), an orphan disease. This group of rare cutaneous
lymphomas of T lymphocytes has a poor prognosis with few
efficacious and safe therapeutic options at advanced
stages.
KIR3DL2 is an inhibitory receptor of the KIR
family, expressed by approximately 65% of patients across all CTCL
subtypes and expressed by up 90% of patients with certain
aggressive CTCL subtypes, in particular, Sézary syndrome. It is
expressed by up to 50% of patients with mycosis fungoides and
peripheral t-cell lymphoma (PTCL). It has a restricted expression
on normal tissues.
About TELLOMAK:
TELLOMAK is a global, open-label, multi-cohort
Phase 2 clinical trial recruiting patients with advanced T-cell
lymphomas (TCL) in the United States and Europe. TELLOMAK is
expected to recruit up to 150 patients, with lacutamab
evaluated:
- As a single agent in approximately 60
patients with Sézary syndrome who have received at least two prior
systemic therapies, including mogamulizumab.
- As a single agent in approximately 90
patients with mycosis fungoides (MF) who have received at least two
systemic therapies.
In patients with MF, the study is designed to
evaluate the effect of lacutamab according to KIR3DL2 expression.
The study comprises two cohorts in MF, testing lacutamab in KIR3DL2
expressing and non-expressing patients determined at baseline.
These cohorts follow a Simon 2-stage design that will terminate
early if treatment is considered futile. The Sézary syndrome cohort
of the study could enable the registration of lacutamab in this
indication.
The primary endpoint of the trial is objective
response rate. Key secondary endpoints are progression-free
survival, duration of response, quality of life and adverse
events.
About Innate Pharma:
Innate Pharma S.A. is a global, clinical-stage
oncology-focused biotech company dedicated to improving treatment
and clinical outcomes for patients through therapeutic antibodies
that harness the immune system to fight cancer.
Innate Pharma’s broad pipeline of antibodies
includes several potentially first-in-class clinical and
preclinical candidates in cancers with high unmet medical need.
Innate is a pioneer in the understanding of
Natural Killer (NK) cell biology and has expanded its expertise in
the tumor microenvironment and tumor-antigens, as well as antibody
engineering. This innovative approach has resulted in a diversified
proprietary portfolio and major alliances with leaders in the
biopharmaceutical industry including Bristol-Myers Squibb, Novo
Nordisk A/S, Sanofi, and a multi-products collaboration with
AstraZeneca.
Headquartered in Marseille, France with a US
office in Rockville, MD, Innate Pharma is listed on Euronext Paris
and Nasdaq in the US.
Learn more about Innate Pharma at
www.innate-pharma.com
Information about Innate Pharma
shares:
ISIN codeTicker
codeLEI |
FR0010331421Euronext: IPH Nasdaq: IPHA9695002Y8420ZB8HJE29 |
Disclaimer on forward-looking
information and risk factors:
This press release contains certain
forward-looking statements, including those within the meaning of
the Private Securities Litigation Reform Act of 1995. The use of
certain words, including “believe,” “potential,” “expect” and
“will” and similar expressions, is intended to identify
forward-looking statements. Although the company believes its
expectations are based on reasonable assumptions, these
forward-looking statements are subject to numerous risks and
uncertainties, which could cause actual results to differ
materially from those anticipated. These risks and uncertainties
include, among other things, the uncertainties inherent in research
and development, including related to safety, progression of and
results from its ongoing and planned clinical trials and
preclinical studies, review and approvals by regulatory authorities
of its product candidates, the Company’s commercialization efforts,
the Company’s continued ability to raise capital to fund its
development and the overall impact of the COVID-19 outbreak on the
global healthcare system as well as the Company’s business,
financial condition and results of operations. For an additional
discussion of risks and uncertainties which could cause the
company's actual results, financial condition, performance or
achievements to differ from those contained in the forward-looking
statements, please refer to the Risk Factors (“Facteurs de Risque")
section of the Universal Registration Document filed with the
French Financial Markets Authority (“AMF”), which is available on
the AMF website http://www.amf-france.org or on Innate Pharma’s
website, and public filings and reports filed with the U.S.
Securities and Exchange Commission (“SEC”), including the Company’s
Annual Report on Form 20-F for the year ended December 31, 2020,
and subsequent filings and reports filed with the AMF or SEC, or
otherwise made public, by the Company.
This press release and the information contained
herein do not constitute an offer to sell or a solicitation of an
offer to buy or subscribe to shares in Innate Pharma in any
country.
For additional information, please contact: |
|
|
|
InvestorsInnate Pharma Tel.: +33
(0)4 30 30 30 30investors@innate-pharma.com |
|
MediaInnate Pharma Tracy Rossin
(Global/US)Tel.: +1 240 801
0076Tracy.Rossin@innate-pharma.comATCG Press Marie
Puvieux (France)Tel.: +33 (0)9 81 87 46
72innate-pharma@atcg-partners.com |
Innate Pharma (EU:IPH)
Graphique Historique de l'Action
De Mar 2024 à Avr 2024
Innate Pharma (EU:IPH)
Graphique Historique de l'Action
De Avr 2023 à Avr 2024